File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A survey on the prevalence and management of hepatitis B after renal transplantation in Asian-Pacific countries

TitleA survey on the prevalence and management of hepatitis B after renal transplantation in Asian-Pacific countries
Authors
Issue Date2004
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/transproceed
Citation
The 8th Congress of the Asian-Society-of-Transplantation, Kualu Lumpur, Malaysia, 23-27 September 2003. In Transplantation Proceedings, 2004, v. 36 n. 7, p. 2126-2127 How to Cite?
AbstractThe carrier rate for hepatitis B virus (HBV) varies from 1% to 2% to 10% in Asian-Pacific countries. A survey involving 12 transplant centers from 11 countries in this region showed that 1% to 25% of kidney transplant recipients were infected with HBV, and up to 60% of these subjects showed abnormal liver biochemistry. While nearly all centers tested anti-HBs in potential kidney transplant recipients, HBV vaccination of nonimmune subjects was routine in only 66.7%. One-third of the surveyed units rejected HBsAg-positive subjects as kidney donors, while the others demonstrated differing policies in choosing the respective recipients. Two units (16.7%) excluded HBsAg-positive patients from kidney transplantation, whereas the others only excluded those with severe liver disease. Heterogeneity also applies to the immunosuppressive regimens, the use of HBV DNA in serial monitoring, and the timing of antiviral therapy in HBsAg-positive kidney transplant recipients. The data showed that despite HBV infection being a significant problem in kidney transplantation, there is a lack of uniform management policy, attributable to the clinical complexity and deficiency of research data. Although improvement in clinical outcome is likely with the advent of nucleoside analogue therapy and better monitoring, the financial implications in the adoption of these recent advances remain realistic concerns.
Persistent Identifierhttp://hdl.handle.net/10722/78058
ISSN
2023 Impact Factor: 0.8
2023 SCImago Journal Rankings: 0.318
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_HK
dc.contributor.authorChapman, Jen_HK
dc.contributor.authorLee, CJen_HK
dc.contributor.authorMorad, Zen_HK
dc.contributor.authorOna, ETen_HK
dc.contributor.authorPark, Ken_HK
dc.contributor.authorPingle, Aen_HK
dc.contributor.authorRizvi, SAHen_HK
dc.contributor.authorShaheen, FAMen_HK
dc.contributor.authorSumethkul, Ven_HK
dc.contributor.authorTang, XDen_HK
dc.contributor.authorWatarai, Yen_HK
dc.date.accessioned2010-09-06T07:38:42Z-
dc.date.available2010-09-06T07:38:42Z-
dc.date.issued2004en_HK
dc.identifier.citationThe 8th Congress of the Asian-Society-of-Transplantation, Kualu Lumpur, Malaysia, 23-27 September 2003. In Transplantation Proceedings, 2004, v. 36 n. 7, p. 2126-2127en_HK
dc.identifier.issn0041-1345en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78058-
dc.description.abstractThe carrier rate for hepatitis B virus (HBV) varies from 1% to 2% to 10% in Asian-Pacific countries. A survey involving 12 transplant centers from 11 countries in this region showed that 1% to 25% of kidney transplant recipients were infected with HBV, and up to 60% of these subjects showed abnormal liver biochemistry. While nearly all centers tested anti-HBs in potential kidney transplant recipients, HBV vaccination of nonimmune subjects was routine in only 66.7%. One-third of the surveyed units rejected HBsAg-positive subjects as kidney donors, while the others demonstrated differing policies in choosing the respective recipients. Two units (16.7%) excluded HBsAg-positive patients from kidney transplantation, whereas the others only excluded those with severe liver disease. Heterogeneity also applies to the immunosuppressive regimens, the use of HBV DNA in serial monitoring, and the timing of antiviral therapy in HBsAg-positive kidney transplant recipients. The data showed that despite HBV infection being a significant problem in kidney transplantation, there is a lack of uniform management policy, attributable to the clinical complexity and deficiency of research data. Although improvement in clinical outcome is likely with the advent of nucleoside analogue therapy and better monitoring, the financial implications in the adoption of these recent advances remain realistic concerns.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/transproceeden_HK
dc.relation.ispartofTransplantation Proceedingsen_HK
dc.rightsTransplantation Proceedings. Copyright © Elsevier Inc.en_HK
dc.subject.meshAsiaen_HK
dc.subject.meshHepatitis B - epidemiologyen_HK
dc.subject.meshHepatitis B Surface Antigens - analysisen_HK
dc.subject.meshHumansen_HK
dc.subject.meshKidney Transplantation - adverse effectsen_HK
dc.subject.meshPostoperative Complications - epidemiology - virologyen_HK
dc.subject.meshPrevalenceen_HK
dc.subject.meshTaiwan - epidemiologyen_HK
dc.titleA survey on the prevalence and management of hepatitis B after renal transplantation in Asian-Pacific countriesen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0041-1345&volume=36&issue=7&spage=2126&epage=2127&date=2004&atitle=A+survey+on+the+prevalence+and+management+of+hepatitis+B+after+renal+transplantation+in+Asian-Pacific+countriesen_HK
dc.identifier.emailChan, TM:dtmchan@hku.hken_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.transproceed.2004.07.066en_HK
dc.identifier.pmid15518771-
dc.identifier.scopuseid_2-s2.0-7044240854en_HK
dc.identifier.hkuros99042en_HK
dc.identifier.volume36en_HK
dc.identifier.issue7en_HK
dc.identifier.spage2126en_HK
dc.identifier.epage2127en_HK
dc.identifier.isiWOS:000224772800095-
dc.publisher.placeUnited Statesen_HK
dc.description.other8th Congress of the Asian-Society-of-Transplantation, Kualu Lumpur, Malaysia, 23-27 September 2003. In Transplantation Proceedings, 2004, v. 36 n. 7, p. 2126-2127-
dc.identifier.scopusauthoridChan, TM=7402687700en_HK
dc.identifier.scopusauthoridChapman, J=35405188900en_HK
dc.identifier.scopusauthoridLee, CJ=7410147965en_HK
dc.identifier.scopusauthoridMorad, Z=6701706079en_HK
dc.identifier.scopusauthoridOna, ET=7004211470en_HK
dc.identifier.scopusauthoridPark, K=7408064896en_HK
dc.identifier.scopusauthoridPingle, A=6603412463en_HK
dc.identifier.scopusauthoridRizvi, SAH=7201786942en_HK
dc.identifier.scopusauthoridShaheen, FAM=35448654000en_HK
dc.identifier.scopusauthoridSumethkul, V=7003656503en_HK
dc.identifier.scopusauthoridTang, XD=7404101059en_HK
dc.identifier.scopusauthoridWatarai, Y=6701717118en_HK
dc.customcontrol.immutablesml 170426 amended-
dc.identifier.issnl0041-1345-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats